Tranexamic Acid in Reducing Blood Loss in Patients with Pelvic Tumors Undergoing Hemipelvectomy Surgery

Description

This early phase I trial studies how well tranexamic acid works in reducing the loss of blood in patients with pelvic tumors undergoing hemipelvectomy surgery. Tranexamic acid decreases blood loss by stabilizing clots and preventing clot lysis in patients undergoing surgery.

Conditions

Pelvic Mass

Study Overview

Study Details

Study overview

This early phase I trial studies how well tranexamic acid works in reducing the loss of blood in patients with pelvic tumors undergoing hemipelvectomy surgery. Tranexamic acid decreases blood loss by stabilizing clots and preventing clot lysis in patients undergoing surgery.

Reducing Blood Loss in Hemipelvectomy Surgery with the Use Tranexamic Acid (TXA)

Tranexamic Acid in Reducing Blood Loss in Patients with Pelvic Tumors Undergoing Hemipelvectomy Surgery

Condition
Pelvic Mass
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Both pediatric and adult patients can be eligible to participate
  • * Cognitively impaired and non-English speakers can be eligible to participate.
  • * Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption
  • * Patient with a history of genetic prothrombotic state
  • * Patient with a history of thromboembolic disease to include pulmonary embolus or other extremity deep venous thrombosis
  • * Patients with thrombosis of the planned site of resection will not be excluded if the thrombus is caused directly by tumor burden or outflow obstruction
  • * Female patients will not be eligible for this study if she is either pregnant or nursing at the time of enrollment
  • * Patients will not be eligible if they have a history of color vision defects
  • * Patients will not be eligible if they have a history of retinal vein or artery occlusion
  • * Patients will not be eligible if they have a history of intracranial hemorrhage in past 6 months
  • * Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid
  • * Patients will not be eligible if they present with moderate to severe decrease in creatinine clearance (estimated glomerular filtration rate \[eGFR\] \< 45 mL/min/1.73m2)
  • * Patients will not be eligible if they present or have a history of seizure disorder

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Valerae O Lewis, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2026-05-31